FDA coverage on Peptide News Digest follows the agency's actual paper trail: approval letters, warning letters, PCAC meeting minutes, 503A bulks list rulings, draft guidance, and Citizen Petitions on substances ranging from semaglutide to BPC-157.
The center of gravity in 2025 and 2026 has been compounding. Once GLP-1 shortages resolved, the agency turned to enforcement — 503A patient-specific compounding versus 503B outsourcing, which APIs sit on which list, what counts as a 'clinical need,' and whether additive formulations count as new drugs. The April 30, 2026 proposal to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list is the most consequential single move so far.
Outside GLP-1, the FDA has been active on peptide-vendor warning letters, advisory committee votes (PCAC, Endocrinologic and Metabolic Drugs), and the long grind of Section 503A's bulks list. Browse the latest below.
FormBlends, a telehealth platform focused on medically supervised GLP-1 and peptide therapy, released its 2026 State of Peptides and GLP-1 Regulation Report on April 28. The report maps how RFK Jr.'s HHS, the FDA Center for Drug Evaluation and Research, and the next-generation obesity pipeline from Eli Lilly, Novo Nordisk, Boehringer Ingelheim, and Roche are reshaping legal access for weight management, metabolic health, and peptide therapy through the end of the decade. The report follows the April 22 formal removal of 12 peptides from FDA Category 2 and previews the July 23-24 PCAC meeting.
JustCare Health published a substantial analysis of the FDA's evolving peptide stance, framing the Category 2 removal as a practical inflection point that begins to resolve the gray-market dynamic that built up after the 2023 restrictions. The piece documents the Alliance for Pharmacy Compounding's position and emphasizes the gap between compounding-pharmacy operational readiness and patient demand. The piece is among the most-read peptide policy articles in the consumer-health press this week.
On April 24 the FDA awarded three National Priority Review Vouchers to companies developing psychedelic therapies: Compass Pathways (psilocybin for treatment-resistant depression), Otsuka Pharmaceutical, and the non-profit Usona Institute (methylone for PTSD). This is the same voucher program that enabled Lilly's Foundayo (orforglipron) to be reviewed in 50 days. The program's expansion into psychedelics signals FDA's continued willingness to use priority vouchers aggressively for novel mental health and metabolic candidates — with peptide developers watching closely ahead of the July PCAC meeting.
The FDA granted accelerated approval April 23 for Regeneron's Otarmeni (lunsotogene parvec-cwha), a gene therapy for certain forms of genetic hearing loss. Otarmeni is the first gene therapy cleared under the FDA's National Priority Voucher program and will be offered to eligible patients at no cost. The approval validates the priority voucher pathway's applicability beyond GLP-1 drugs and establishes regulatory precedent that peptide developers may invoke if the July PCAC meeting produces favorable reclassification recommendations.
Yahoo published an April 23 consumer-facing explainer titled "Wait, So Are Peptides Legal Now?" — the most widely-circulated translation of last week's FDA Category 2 removal for a mainstream audience. The piece walks through which 12 peptides were removed from the restricted list, what the July 23-24 PCAC meeting will actually decide, the distinction between reclassification and FDA approval, and the practical implications for compounding pharmacies and patients. The article marks the peptide-regulation story's transition into general consumer awareness.
Hyman, Phelps & McNamara's FDA Law Blog published a comprehensive two-part analysis April 22 walking compounders and peptide industry stakeholders through the Federal Register notice, the July 23-24 PCAC meeting structure, the distinction between Category 2 removal and Section 503A Bulk Drug Substances List inclusion, and the notice-and-comment rulemaking that must follow any PCAC recommendation. The analysis emphasizes that the July 9, 2026 written comment deadline and June 30 oral presentation notification are critical inflection points for industry engagement.
Effective April 22, BPC-157, TB-500, Semax, Epitalon, MOTS-c and seven other peptides were formally removed from the FDA's 503A Category 2 significant-safety-concerns list after original nominators withdrew submissions. The FDA Pharmacy Compounding Advisory Committee will meet July 23-24 to decide whether to add these peptides to the 503A bulks list, which would restore legal compounding under prescription.
A Bloomberg opinion piece published April 21 argues that the FDA's planned July 23-24 PCAC review of seven peptides (BPC-157, MOTS-c, KPV, among others) and RFK Jr.'s broader push to reclassify 14 of 19 Category 2 peptides doesn't give consumers the evidence-based safety and efficacy data they need. The piece frames the ongoing compounding debate as a consumer-protection gap that clinical trial evidence — not political reclassification — should fill.
A University of Colorado Anschutz-led secret shopper study presented at Obesity Medicine Association 2026 surveyed 75 weight-loss clinics and medspas across two US states. 69 of 74 still offered compounded semaglutide and 65 of 74 offered compounded tirzepatide despite FDA resolving the name-brand shortages. Four source facilities had received FDA warnings or state licensing discipline since 2023 — three related to sterile compounding. Many clinics report using 'additive' formulations to skirt compounding restrictions.
A BioCentury analysis argues the FDA's April 16 decision to convene a July Pharmacy Compounding Advisory Committee meeting on 12 previously restricted peptides reflects HHS Secretary RFK Jr.'s enthusiasm more than scientific evidence. The outlet warns that most of the peptides under review — for conditions spanning ulcerative colitis, wound healing, obesity, insomnia, and neurological disorders — lack robust clinical safety or efficacy data, and that ideology is increasingly shaping agency decisions.
BioSpace analysis frames the ACHIEVE-4 results as a direct answer to the FDA's April 1 letter requesting post-market liver injury and cardiovascular data. The 'outstanding' type 2 diabetes data, combined with cardiovascular safety and all-cause death reductions, strengthens Lilly's position ahead of its Q2 FDA submission and could reduce regulatory friction for the oral GLP-1 franchise.
STAT News analysis of the composition of the July 23-24 Pharmacy Compounding Advisory Committee suggests panelists are likely to vote in favor of broader peptide access. The panel will review BPC-157 (ulcerative colitis), KPV (wound healing), TB-500, MOTS-c, emideltide, semax, and epitalon — largely aligning with RFK Jr.'s February 2026 pledge to move 14 restricted peptides back to Category 1.
Enhanced, an elite sports performance and direct-to-consumer peptide company, formally welcomed the FDA's Pharmacy Compounding Advisory Committee meeting schedule. CEO Maximilian Martin stated the reclassification will move peptides 'out of the grey market' and enable licensed compounding access. Enhanced plans to expand its Live Enhanced platform to offer additional peptides once they are formally moved to Category 1.
The Washington Post framed the FDA's upcoming July peptide panel through the lens of the exploding wellness craze, noting peptides are pitched as quick fixes for muscle building, injury healing, and anti-aging with minimal supporting research. When the FDA added 19 peptides to its restricted list in 2023, it cited safety risks including cancer and liver, kidney, and heart problems — concerns that have not been resolved.
The FDA announced it will convene the Pharmacy Compounding Advisory Committee on July 23-24 to evaluate whether seven or more peptides — including BPC-157, TB-500, and other popular wellness peptides — should be added to the list of substances eligible for pharmacy compounding. The announcement follows HHS Secretary RFK Jr.'s February pledge to reclassify 14 restricted peptides.
The GLP-1 mass tort litigation (MDL 3094) before Judge Karen Marston in the Eastern District of Pennsylvania now includes 3,363 cases alleging gastroparesis and other injuries. Expert discovery closed in late March, with Daubert motions due April 28 and summary judgment motions due April 30. A Science Day on vision loss claims is set for June 2.
Scientific American reports that the FDA's decision to convene an expert advisory panel — rather than unilaterally reclassifying peptides — signals a more cautious approach than RFK Jr.'s original February pledge suggested. The panel will weigh limited safety data against surging consumer demand and a growing black market for unregulated peptide products.
The FDA asked Eli Lilly for additional safety data on liver injury linked to Foundayo (orforglipron), plus post-marketing trials to assess cardiovascular event risk and delayed gastric emptying. A lactation study was also required. The letter, signed April 1, was published April 14 — just two weeks after the drug's fast-track approval under the National Priority Voucher program.